{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:14:35Z","timestamp":1778692475536,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Argorna Pharmaceuticals Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-45429-w","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:39:02Z","timestamp":1774431542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterologous RBMRNA-405 mRNA booster enhances humoral immunity post-inactivated COVID-19 vaccination: a randomized clinical trial in adults and older through 12 months"],"prefix":"10.1038","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05897190","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiaolan","family":"Yong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"45429_CR1","unstructured":"World Health Organization 2023 data.who.int, WHO Coronavirus (COVID-19) dashboard\u2009>\u2009Vaccines [Dashboard] (2024). https:\/\/data.who.int\/dashboards\/covid19\/vaccines."},{"issue":"7881","key":"45429_CR2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","volume":"598","author":"S Mallapaty","year":"2021","unstructured":"Mallapaty, S. China\u2019s COVID vaccines have been crucial - now immunity is waning. Nature 598 (7881), 398\u2013399. https:\/\/doi.org\/10.1038\/d41586-021-02796-w (2021).","journal-title":"Nature"},{"issue":"10296","key":"45429_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398 (10296), 213\u2013222. https:\/\/doi.org\/10.1016\/S0140-6736(21)01429-X (2021).","journal-title":"Lancet"},{"key":"45429_CR4","unstructured":"World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac (version 15 March 2022). WHO (2021). https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1."},{"key":"45429_CR5","doi-asserted-by":"publisher","unstructured":"Chavda, V. P. et al. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. Front. Immunol. 13, 961198. https:\/\/doi.org\/10.3389\/fimmu.2022.961198 (2022).","DOI":"10.3389\/fimmu.2022.961198"},{"issue":"10","key":"45429_CR6","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3390\/vaccines10101655","volume":"10","author":"AA Rabaan","year":"2022","unstructured":"Rabaan, A. A. et al. A comprehensive review on the current vaccines and their efficacies to Combat SARS-CoV-2 variants. Vaccines (Basel). 10 (10), 1655. https:\/\/doi.org\/10.3390\/vaccines10101655 (2022).","journal-title":"Vaccines (Basel)"},{"issue":"21","key":"45429_CR7","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMc2115596","volume":"385","author":"AY Collier","year":"2021","unstructured":"Collier, A. Y. et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. N Engl. J. Med. 385 (21), 2010\u20132012. https:\/\/doi.org\/10.1056\/NEJMc2115596 (2021).","journal-title":"N Engl. J. Med."},{"issue":"6561","key":"45429_CR8","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.abj4176","volume":"373","author":"A Pegu","year":"2021","unstructured":"Pegu, A. et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science 373 (6561), 1372\u20131377. https:\/\/doi.org\/10.1126\/science.abj4176 (2021).","journal-title":"Science"},{"key":"45429_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","volume":"22","author":"M Lipsitch","year":"2022","unstructured":"Lipsitch, M. et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat. Rev. Immunol. 22, 57\u201365. https:\/\/doi.org\/10.1038\/s41577-021-00662-4 (2022).","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"45429_CR10","doi-asserted-by":"publisher","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","volume":"6","author":"F Menegale","year":"2023","unstructured":"Menegale, F. et al. Evaluation of waning of SARS-CoV-2 vaccine\u2013induced immunity: a systematic review and meta-analysis. JAMA Netw. Open. 6 (5), e2310650. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.10650 (2023).","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"45429_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11427-022-2171-2","volume":"66","author":"C Zhang","year":"2023","unstructured":"Zhang, C. & Zhang, B. RNA therapeutics: updates and future potential. Sci. China Life Sci. 66 (1), 12\u201330. https:\/\/doi.org\/10.1007\/s11427-022-2171-2 (2023).","journal-title":"Sci. China Life Sci."},{"issue":"5","key":"45429_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/s2213-2600(23)00015-2","volume":"11","author":"N Wu","year":"2023","unstructured":"Wu, N. et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir. Med. 11 (5), 439\u2013452. https:\/\/doi.org\/10.1016\/s2213-2600(23)00015-2 (2023).","journal-title":"Lancet Respir. Med."},{"issue":"10308","key":"45429_CR13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/s0140-6736(21)02046-8","volume":"398","author":"PR Krause","year":"2021","unstructured":"Krause, P. R. et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 398 (10308), 1377\u20131380. https:\/\/doi.org\/10.1016\/s0140-6736(21)02046-8 (2021).","journal-title":"Lancet"},{"issue":"11","key":"45429_CR14","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","volume":"27","author":"A Choi","year":"2021","unstructured":"Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat. Med. 27 (11), 2025\u20132031. https:\/\/doi.org\/10.1038\/s41591-021-01527-y (2021).","journal-title":"Nat. Med."},{"issue":"10324","key":"45429_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SAC Clemens","year":"2022","unstructured":"Clemens, S. A. C. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399 (10324), 521\u2013529. https:\/\/doi.org\/10.1016\/S0140-6736(22)00094-0 (2022).","journal-title":"Lancet"},{"issue":"1","key":"45429_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/vaccines10010086","volume":"10","author":"S Kanokudom","year":"2022","unstructured":"Kanokudom, S. et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines (Basel). 10 (1), 86. https:\/\/doi.org\/10.3390\/vaccines10010086 (2022). Published 2022 Jan 6.","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"45429_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","volume":"28","author":"E P\u00e9rez-Then","year":"2022","unstructured":"P\u00e9rez-Then, E. et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat. Med. 28 (3), 481\u2013485. https:\/\/doi.org\/10.1038\/s41591-022-01705-6 (2022).","journal-title":"Nat. Med."},{"issue":"3","key":"45429_CR18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","volume":"28","author":"SMS Cheng","year":"2022","unstructured":"Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med. 28 (3), 486\u2013489. https:\/\/doi.org\/10.1038\/s41591-022-01704-7 (2022).","journal-title":"Nat. Med."},{"key":"45429_CR19","doi-asserted-by":"publisher","unstructured":"Zuo, F. et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat. Commun. 13 (1), 2670. https:\/\/doi.org\/10.1038\/s41467-022-30340-5 (2022).","DOI":"10.1038\/s41467-022-30340-5"},{"key":"45429_CR20","doi-asserted-by":"publisher","first-page":"1195299","DOI":"10.3389\/fimmu.2023.1195299","volume":"14","author":"Q Ma","year":"2023","unstructured":"Ma, Q. et al. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern. Front. Immunol. 14, 1195299. https:\/\/doi.org\/10.3389\/fimmu.2023.1195299 (2023).","journal-title":"Front. Immunol."},{"issue":"10","key":"45429_CR21","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3390\/vaccines10101698","volume":"10","author":"Q Ma","year":"2022","unstructured":"Ma, Q. et al. Immunization with a prefusion SARS- CoV-2 spike protein vaccine (RBMRNA-176) protects against viral challenge in mice and nonhuman primates. Vaccines 10 (10), 1698. https:\/\/doi.org\/10.3390\/vaccines10101698 (2022).","journal-title":"Vaccines"},{"key":"45429_CR22","doi-asserted-by":"publisher","unstructured":"Lederer, K. et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody Gener. Immun. 53(6), 1281\u20131295e5. https:\/\/doi.org\/10.1016\/j.immuni.2020.11.009 (2020).","DOI":"10.1016\/j.immuni.2020.11.009"},{"issue":"4","key":"45429_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","volume":"185","author":"PA Mudd","year":"2021","unstructured":"Mudd, P. A. et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185 (4), 603\u2013613e15. https:\/\/doi.org\/10.1016\/j.cell.2021.12.026 (2021).","journal-title":"Cell"},{"issue":"3","key":"45429_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","volume":"28","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 28 (3), 472\u2013476. https:\/\/doi.org\/10.1038\/s41591-022-01700-x (2022).","journal-title":"Nat. Med."},{"issue":"1","key":"45429_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2021.12.004","volume":"30","author":"A Tauzin","year":"2021","unstructured":"Tauzin, A. et al. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell. Host Microbe. 30 (1), 97\u2013109e5. https:\/\/doi.org\/10.1016\/j.chom.2021.12.004 (2021).","journal-title":"Cell. Host Microbe"},{"issue":"11","key":"45429_CR26","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/nejmoa2116414","volume":"386","author":"RL Atmar","year":"2022","unstructured":"Atmar, R. L. et al. Homologous and heterologous COVID-19 booster vaccinations. N. Engl. J. Med. 386 (11), 1046\u20131057. https:\/\/doi.org\/10.1056\/nejmoa2116414 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"45429_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1056\/NEJMoa2116747","volume":"386","author":"RSG Sablerolles","year":"2022","unstructured":"Sablerolles, R. S. G. et al. Immunogenicity and reactogenicity of vaccine boosters after Ad26.COV2.S priming. N. Engl. J. Med. 386 (10), 951\u2013963. https:\/\/doi.org\/10.1056\/NEJMoa2116747 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"45429_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/s1473-3099(22)00271-7","volume":"22","author":"A Munro","year":"2022","unstructured":"Munro, A. et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet. Infect. Dis. 22 (8), 1131\u20131141. https:\/\/doi.org\/10.1016\/s1473-3099(22)00271-7 (2022).","journal-title":"Lancet. Infect. Dis"},{"issue":"20","key":"45429_CR29","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/nejmoa2200674","volume":"386","author":"ED Moreira","year":"2022","unstructured":"Moreira, E. D. et al. Safety and efficacy of a third dose of BNT162B2 COVID-19 vaccine. N. Engl. J. Med. 386 (20), 1910\u20131921. https:\/\/doi.org\/10.1056\/nejmoa2200674 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"45429_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","volume":"28","author":"E P\u00e9rez-Then","year":"2022","unstructured":"P\u00e9rez-Then, E. et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat. Med. 28 (3), 481\u2013488. https:\/\/doi.org\/10.1038\/s41591-022-01705-6 (2022).","journal-title":"Nat. Med."},{"issue":"12","key":"45429_CR31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.vaccine.2023.01.032","volume":"41","author":"SI Mallah","year":"2023","unstructured":"Mallah, S. I. et al. Safety and efficacy of COVID-19 prime-boost vaccinations: homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine 41 (12), 1925\u20131933. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.032 (2023).","journal-title":"Vaccine"},{"key":"45429_CR32","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1126\/scitranslmed.ade6023","volume":"15","author":"BA Filardi","year":"2023","unstructured":"Filardi, B. A. et al. Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose. Sci. Transl. Med. 15, 6023. https:\/\/doi.org\/10.1126\/scitranslmed.ade6023 (2023).","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"45429_CR33","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/s2214-109x(22)00112-7","volume":"10","author":"A Jara","year":"2022","unstructured":"Jara, A. et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Global Health. 10 (6), e798\u2013e806. https:\/\/doi.org\/10.1016\/s2214-109x(22)00112-7 (2022).","journal-title":"Lancet Global Health"},{"issue":"1","key":"45429_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/14760584.2024.2333952","volume":"23","author":"G Pastore","year":"2024","unstructured":"Pastore, G. et al. Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant. Expert Rev. Vaccines. 23 (1), 432\u2013444. https:\/\/doi.org\/10.1080\/14760584.2024.2333952 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"45429_CR35","doi-asserted-by":"publisher","first-page":"107042","DOI":"10.1016\/j.actatropica.2023.107042","volume":"248","author":"CM Trombetta","year":"2023","unstructured":"Trombetta, C. M. et al. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy. Acta Trop. 248, 107042. https:\/\/doi.org\/10.1016\/j.actatropica.2023.107042 (2023).","journal-title":"Acta Trop."},{"issue":"10","key":"45429_CR36","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3390\/vaccines9101092","volume":"9","author":"JL Bayart","year":"2021","unstructured":"Bayart, J. L. et al. Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers. Vaccines 9 (10), 1092. https:\/\/doi.org\/10.3390\/vaccines9101092 (2021).","journal-title":"Vaccines"},{"key":"45429_CR37","doi-asserted-by":"publisher","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, 6529. https:\/\/doi.org\/10.1126\/science.abf4063 (2021).","DOI":"10.1126\/science.abf4063"},{"key":"45429_CR38","doi-asserted-by":"publisher","unstructured":"Iyer, A. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. 5, 52. https:\/\/doi.org\/10.1126\/sciimmunol.abe0367 (2020).","DOI":"10.1126\/sciimmunol.abe0367"},{"key":"45429_CR39","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg, Y. et al. Waning immunity after the BNT162b2 Vaccine in Israel. N Engl. J. Med. 385, e85. https:\/\/doi.org\/10.1056\/NEJMoa2114228 (2021).","journal-title":"N Engl. J. Med."},{"issue":"5","key":"45429_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/trstmh\/trab045","volume":"115","author":"EM Choi","year":"2021","unstructured":"Choi, E. M. COVID-19 vaccines for low- and middle-income countries. Trans. R. Soc. Trop. Med. Hyg. 115 (5), 447\u2013456. https:\/\/doi.org\/10.1093\/trstmh\/trab045 (2021).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45429-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:23:51Z","timestamp":1778689431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45429-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45429"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45429-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was an investigator-initiated trial (IIT). The sponsor\/funder had no role in study design, data collection, data analysis, data interpretation, or writing of the trial report. This trial was sponsored by Argorna Pharmaceuticals, which provided the study vaccine RBMRNA-405. RBMRNA-405 was co-developed by Argorna and RiboBio. YO and BZ are employees of Argorna. CZ is an employee of RiboBio. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14928"}}